WALTHAM, Mass., June 5 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that Nazneen Aziz, Ph.D., Vice President of Research and Development, will present findings that highlight significant associations between perilipin gene variants and response to weight-loss in overweight individuals at the American Diabetes Association's 69th Scientific Sessions in New Orleans, LA. Dr. Aziz will present the Company's research at 8 a.m. on Saturday, June 6, 2009, in Room 255 of the Morial Convention Center.
Interleukin Genetics and its collaborators conducted the research on DNA samples from the NIH-sponsored CALERIE (Comprehensive Assessment of the Long Term Effects of Restricting Intake of Energy) pilot study. CALERIE evaluated high and low glycemic load with a 30 percent calorie-restricted diets in individuals during a tightly-controlled, one-year period. The diets were prepared at the institution and provided to the study subjects for a period of six months and followed by extensive dietary guidance for the next six months. Compliance to the diet was monitored using a non-radioactive isotope mass spectrometric method using doubly labeled water technique several times during the study period. The Company's research found that variations within the Perilipin genes are associated with resistance to body weight and fat loss in overweight study subjects who were provided a calorie restricted diet.
"Perilipin is a protein in the phospholipid outer layer of fat cells that plays an important role in both the storage and metabolism of triglycerides. This study confirms the results of other dietary intervention studies that found certain genetic variants within the perilipin gene can cause resistance to weight loss in individuals even when they follow a low-carbohydrate, low-calorie diet plan for an extend
'/>"/>
| SOURCE Interleukin Genetics, Inc. Copyright©2009 PR Newswire. All rights reserved |